These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 3166903)

  • 1. The logistics of broader pre-clinical evaluation of potential anti-cancer agents with reference to anti-tumour activity and toxicity of mitozolomide.
    Bibby MC; Double JA; Wahed IA; Hirbawi N; Baker TG
    Br J Cancer; 1988 Aug; 58(2):139-43. PubMed ID: 3166903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of mitozolomide (NSC 353451), a new imidazotetrazine, against xenografts from human melanomas, sarcomas, and lung and colon carcinomas.
    Fodstad O; Aamdal S; Pihl A; Boyd MR
    Cancer Res; 1985 Apr; 45(4):1778-86. PubMed ID: 3978640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experimental antitumor activity against murine tumor model systems of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3 H)-one (mitozolomide), a novel broad-spectrum agent.
    Hickman JA; Stevens MF; Gibson NW; Langdon SP; Fizames C; Lavelle F; Atassi G; Lunt E; Tilson RM
    Cancer Res; 1985 Jul; 45(7):3008-13. PubMed ID: 4005840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancing hemopoietic drug resistance: a rationale for reconsidering the clinical use of mitozolomide.
    Fairbairn LJ; Chinnasamy N; Lashford LS; Chinnasamy D; Rafferty JA
    Cancer Gene Ther; 2000 Feb; 7(2):233-9. PubMed ID: 10770631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumour imidazotetrazines--VIII. Uptake and decomposition of a novel antitumour agent mitozolomide (CCRG 81010; M and B 39565; NSC 353451) in TLX5 mouse lymphoma in vitro.
    Horgan CM; Tisdale MJ
    Biochem Pharmacol; 1985 Jan; 34(2):217-21. PubMed ID: 3966923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unique chemosensitivity of MAC 16 tumours to flavone acetic acid (LM975, NSC 347512).
    Bibby MC; Double JA; Loadman PM
    Br J Cancer; 1988 Sep; 58(3):341-4. PubMed ID: 3179187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of mitozolomide (M & B 39,565) in colorectal and breast cancer.
    Herait P; Rougier P; Oliveira J; Delgado FM; May-Levin F; Hayat M; Armand JP
    Invest New Drugs; 1988 Dec; 6(4):323-5. PubMed ID: 3229944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-tumour activity of TCNU in a panel of transplantable murine colon tumours.
    Bibby MC; Double JA; Morris CM
    Eur J Cancer Clin Oncol; 1988 Aug; 24(8):1361-4. PubMed ID: 3181257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I clinical trial of mitozolomide.
    Newlands ES; Blackledge G; Slack JA; Goddard C; Brindley CJ; Holden L; Stevens MF
    Cancer Treat Rep; 1985; 69(7-8):801-5. PubMed ID: 4016790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of mitozolomide in patients with advanced ovarian cancer. A study of the EORTC Gynecological Cancer Cooperative Group.
    Neijt JP; van der Burg ME; Guastalla JP; George M; Piccart M; Vermorken J; Carnino F; Rotmensz N
    Acta Oncol; 1989; 28(5):663-5. PubMed ID: 2590542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effects of mitozolomide (M & B 39125, NSC 353451) and a series of standard anticancer drugs on mouse testis.
    Wahed I; Bibby MC; Baker TG
    Arch Toxicol Suppl; 1987; 11():277-80. PubMed ID: 3477182
    [No Abstract]   [Full Text] [Related]  

  • 12. Activity and distribution studies of etoposide and mitozolomide in vivo and in vitro against human choriocarcinoma cell lines.
    Brindley CJ; Pedley RB; Antoniw P; Newlands ES
    Cancer Chemother Pharmacol; 1987; 19(3):221-5. PubMed ID: 3581415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumour imidazotetrazines--IV. An investigation into the mechanism of antitumour activity of a novel and potent antitumour agent, mitozolomide (CCRG 81010, M & B 39565; NSC 353451).
    Horgan CM; Tisdale MJ
    Biochem Pharmacol; 1984 Jul; 33(14):2185-92. PubMed ID: 6147140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine.
    Stevens MF; Hickman JA; Langdon SP; Chubb D; Vickers L; Stone R; Baig G; Goddard C; Gibson NW; Slack JA
    Cancer Res; 1987 Nov; 47(22):5846-52. PubMed ID: 3664486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of cellular esterases by the antitumour imidazotetrazines mitozolomide and temozolomide: demonstration by flow cytometry and conventional spectrofluorimetry.
    Dive C; Workman P; Watson JV
    Cancer Chemother Pharmacol; 1989; 25(3):149-55. PubMed ID: 2557170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumour imidazotetrazines, Part IX. The pharmacokinetics of mitozolomide in mice.
    Goddard C; Slack JA; Stevens MF
    Br J Cancer; 1985 Jul; 52(1):37-41. PubMed ID: 4015951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thiazolidinyl- and perhydrothiazinylphosphamidesters: toxicity and preliminary antitumour evaluation.
    Voelcker G; Bielicki L; Hohorst HJ
    J Cancer Res Clin Oncol; 1997; 123(11-12):623-31. PubMed ID: 9620221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of phthalmustine, a new anticancer compound. I. Effect on Dalton's ascitic lymphoma in mice.
    Bhattacharya S; Ganguly C; Sanyal U; Das S
    Neoplasma; 1994; 41(1):35-8. PubMed ID: 8202193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitozolomide (NSC 353451), a new active drug in the treatment of malignant melanoma. Phase II trial in patients with advanced disease.
    Gundersen S; Aamdal S; Fodstad O
    Br J Cancer; 1987 Apr; 55(4):433-5. PubMed ID: 3580266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of N-[N'-(2-chloroethyl)-N'-nitrosocarbamoyl]-alanine and derivatives against transplantable adenocarcinomata of the mouse colon (MAC).
    Bibby MC; Double JA
    J Cancer Res Clin Oncol; 1986; 112(1):47-9. PubMed ID: 3733867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.